ENDRA Life Sciences (NDRA) Cash from Financing Activities (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Cash from Financing Activities for 11 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 354.15% year-over-year to $3.9 million in Q2 2026; TTM through Jun 2026 was $8.9 million, a 784.38% increase from a year earlier, with the FY2025 full-year figure at $5.7 million, down 26.59% from the prior year.
• Cash from Financing Activities was $3.9 million for Q2 2026 at ENDRA Life Sciences, up from $263747.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $7.5 million in Q2 2022 and troughed at $1683.0 in Q3 2024.
• A 5-year average of $2.4 million and a median of $985623.5 in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities sank 99.85% in 2024 and jumped 8780.93% in 2025, its largest moves.
• Over 5 years, Cash from Financing Activities stood at $7.5 million in 2022, then sank by 77.85% to $1.7 million in 2023, then plunged by 99.9% to $1683.0 in 2024, then soared by 272035.41% to $4.6 million in 2025, then dropped by 14.98% to $3.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.9 million (Q2 2026), $263747.0 (Q1 2026), and $4.6 million (Q4 2025), per Business Quant data.